Designed to overcome challenges in high-throughput screening for drug discovery, the Echo® MS+ system eliminates the need for extensive method development. By introducing flexible workflows for both small and large molecules, the system leverages high-resolution mass spectrometry, providing unparalleled selectivity and sensitivity compared to traditional analytical tools.

Jose Castro-Perez, Vice President of Product Management at SCIEX, emphasized, "Building on the speed and fidelity of results that this technology can deliver by integrating it with high-resolution mass spectrometry is going to enable us to develop new and novel workflows across a range of molecule types for high-throughput screening applications."

The Echo® MS+ system promises a significant reduction in time, cost, and risk during the early stages of drug development by combining rapid analysis, high data quality, and minimal sample and reagent consumption. This advancement empowers researchers in drug discovery to make quicker and more confident decisions in hit identification and iterative lead optimization, expediting the drug development pipeline.

Furthermore, SCIEX plans to collaborate with global partners at its Echo® MS Center of Excellence to continue developing innovative workflows for the Echo® MS+ system. Castro-Perez added, "The goal is to address key unmet analytical needs with this disruptive technology."

SCIEX's Echo® MS+ system marks a significant stride towards revolutionizing high-throughput screening in drug discovery, promising a future of accelerated decision-making and increased efficiency in the pharmaceutical industry.